Vitamin D3 Shields the Aging Brain Against Neurodegeneration
A 2025 narrative review reveals how vitamin D3 protects neurons via genomic, anti-inflammatory, and DNA-repair pathways relevant to AD, PD, and MS.
Summary
This 2025 narrative review from the Medical University of Bialystok synthesizes evidence on how vitamin D3 exerts neuroprotective effects across multiple mechanisms. VDR receptors expressed throughout the CNS mediate genomic actions—upregulating BDNF, GDNF, and CNTF while suppressing excitotoxic calcium signaling. Non-genomic pathways via PDIA3 stabilize intracellular calcium through PKC, PI3K, and MAPK cascades. Vitamin D3 also modulates neuroinflammation by shifting T-cell balance toward anti-inflammatory Treg phenotypes. Deficiency correlates with cognitive decline, shorter telomere length, and elevated Alzheimer's biomarkers, while supplementation shows promise in selected clinical studies for improving cognition and reducing amyloid-β. Influence on DNA-repair genes NRF2, OGG1, MYH, and MTH1 links vitamin D3 to cellular aging. Heterogeneity across studies limits firm conclusions, and standardized research is urgently needed.
Detailed Summary
Vitamin D3 has long been associated with bone health, but a growing body of research positions it as a critical modulator of nervous system integrity. This 2025 narrative review, published in Nutrients by researchers from the Medical University of Bialystok, comprehensively examines how vitamin D3 may protect the brain against age-related neurodegeneration—covering molecular mechanisms, clinical evidence, and disease-specific findings in Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and autism spectrum disorder (ASD).
The authors searched PubMed, Web of Science, and Google Scholar for literature spanning 1969–2025 using terms including 'vitamin D3,' 'neuroprotection,' 'neuroplasticity,' 'telomere,' and individual disease names. Vitamin D3 metabolism begins with UV-driven skin conversion of 7-dehydrocholesterol to cholecalciferol, hepatic 25-hydroxylation via CYP2R1, and renal 1α-hydroxylation via CYP27B1 to yield biologically active 1,25(OH)2D. Critically, this final step also occurs locally in brain tissue, and VDRs are expressed widely across neurons, astrocytes, monocytes, and activated lymphocytes.
Key neuroprotective mechanisms identified include: (1) Genomic actions—VDR-RXR heterodimers bind vitamin D response elements (VDREs) to upregulate BDNF, GDNF, and CNTF, promoting neuronal survival and synaptic plasticity, while simultaneously downregulating L-type voltage-gated calcium channels to prevent excitotoxicity. (2) Non-genomic actions—membrane receptor PDIA3 activates PKC and ERK1/2 MAPK pathways, stabilizing intracellular calcium within seconds. (3) Immunomodulation—1,25(OH)2D3 suppresses pro-inflammatory Th1 cytokines (IL-2, IL-6, IFN-γ) and promotes Treg differentiation, reducing neuroinflammation relevant to MS and PD. (4) DNA repair and oxidative stress defense—vitamin D3 upregulates NRF2, OGG1, MYH, and MTH1, linking it to genomic stability and cellular senescence resistance. (5) Telomere biology—deficiency correlates with shorter leukocyte telomere length, and supplementation studies report telomere lengthening, suggesting a role in slowing biological aging.
For specific diseases: in AD, low 25(OH)D is associated with cognitive decline (MoCA scores), elevated amyloid-β, and tau pathology; supplementation trials and meta-analyses report improved cognition and reduced amyloid biomarkers in selected populations. In PD, VDRs are abundant in dopaminergic substantia nigra neurons; vitamin D stimulates NGF and GDNF expression, reduces α-synuclein aggregation, and modulates dopamine synthesis via tyrosine hydroxylase regulation. In MS, vitamin D attenuates Th1/Th17-mediated demyelination and promotes remyelination through oligodendrocyte precursor support; epidemiological data link latitude-dependent sun exposure to MS prevalence. In ASD, maternal vitamin D deficiency during pregnancy is associated with altered fetal brain development, serotonin dysregulation, and elevated inflammatory markers.
Supplementation guidance varies internationally, with most guidelines suggesting 600–2000 IU/day for adults, upper limits around 4000 IU/day, and toxicity risk emerging above 100–150 ng/mL serum 25(OH)D. The review emphasizes that optimal dosing must account for age, BMI, sun exposure, and comorbidities. Critically, the authors acknowledge significant heterogeneity in study designs, populations, deficiency thresholds, and outcome measures, limiting causal inference and the generalizability of findings.
Key Findings
- VDR activation in the brain upregulates BDNF, GDNF, and CNTF, supporting neuronal survival and synaptic plasticity.
- Vitamin D3 deficiency correlates with shorter leukocyte telomere length; supplementation may reverse this, slowing cellular aging.
- 1,25(OH)2D3 shifts immune balance from pro-inflammatory Th1/Th17 toward anti-inflammatory Tregs, reducing neuroinflammatory damage.
- Vitamin D3 upregulates DNA-repair genes NRF2, OGG1, MYH, and MTH1, linking it to oxidative stress defense and genomic stability.
- Low serum 25(OH)D is consistently associated with cognitive decline and elevated amyloid-β; supplementation shows promise in selected AD trials.
Methodology
This is a narrative review searching PubMed, Web of Science, and Google Scholar for studies from 1969–2025 using structured keyword combinations. No formal PRISMA protocol, systematic inclusion/exclusion criteria, or risk-of-bias assessment were applied. Studies included both original research and review articles covering mechanistic, clinical, and translational evidence.
Study Limitations
As a narrative review without systematic methodology, selection bias and lack of methodological quality appraisal limit the strength of conclusions. Included studies varied widely in supplementation dose, deficiency thresholds, population characteristics, and outcome measures, introducing substantial heterogeneity. Causal inference cannot be established from observational data, and confounders such as age, BMI, sun exposure, and comorbidities were not uniformly controlled.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.